Alivus Life Sciences Profit & Loss Annual

BSE: 543322 | NSE: ALIVUS | ISIN: INE03Q201024 | Sector: Biotechnology & Drugs

1,048.95 +14.60 (1.41%)Updated : 28 Apr 2025

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	2,283.21	2,161.22	2,123.21	1,885.17
Total Revenue	2,283.21	2,161.22	2,123.21	1,885.17
Costof Revenue Total	1,002.01	1,014.09	1,042.89	905.50
Gross Profit	1,281.20	1,147.13	1,080.33	979.67
Selling/ General/ Admin Expenses Total	576.07	478.71	463.52	384.55
Depreciation/ Amortization	53.45	42.09	37.88	33.39
Other Operating Expenses Total	29.55	25.57	-0.32	-0.38
Total Operating Expense	1,661.08	1,560.46	1,543.97	1,323.06
Operating Income	622.14	600.76	579.25	562.10
Interest Inc( Exp) Net- Non- Op Total	9.86	28.27	-13.51	-90.50
Gain( Loss)on Saleof Assets	-0.70	-0.56	-0.74	-0.58
Other Net	0.00	0.14	-0.07	-0.08
Net Income Before Taxes	631.29	628.61	564.93	470.94
Provisionfor Income Taxes	160.40	161.65	146.20	119.36
Net Income After Taxes	470.89	466.96	418.72	351.58
Net Income Before Extra Items	470.89	466.96	418.72	351.58
Net Income	470.89	466.96	418.72	351.58
Income Availableto Com Excl Extra Ord	470.89	466.96	418.72	351.58
Income Availableto Com Incl Extra Ord	470.89	466.96	418.72	351.58
Diluted Net Income	470.89	466.96	418.72	351.58
Diluted Weighted Average Shares	12.27	12.25	11.75	12.25
Diluted EPS Excluding Extra Ord Items	38.38	38.11	35.63	28.69
DPS- Common Stock Primary Issue	22.50	21.00	21.00	-
Diluted Normalized EPS	38.43	38.14	35.67	28.73
period Length	12.00	12.00	12.00	12.00
period Type	-	-	-	-